Basic Information
Optivate
INJECTION, POWDER, FOR SOLUTION
Regulatory Information
SIN13191P
March 16, 2006
Prescription Only
Therapeutic
INTRAVENOUS
August 10, 2023
June 3, 2025
XB02BD06
Company Information
EURO ASIA MEDICO PTE. LTD.
EURO ASIA MEDICO PTE. LTD.
Active Ingredients
von Willebrand Factor (co-exist with Factor VIII)
Strength: 260 iu/ml
Factor VIII
Strength: 100 iu/ml
Detailed Information
Contraindications
**4.3 Contra-indications** Hypersensitivity to the active substance or to any of the excipients.
Indication Information
**4.1 Therapeutic indications** Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency).